Hepatocellular carcinoma after treatment of hepatitis C with direct-acting antivirals: a critical re-appraisal

Abstract

Soon after introducing direct-acting antiviral agents (DAAs) for chronic hepatitis C treatment, there began a debate over the possibility of hepatocellular carcinoma (HCC) after viral clearance. Although several reports suggested that the question has been answered negatively, other reports suggested the opposite. The present review presents data in favor and against the null hypothesis and analyzes the scientific background of the possible participation of DAAs in HCC development. The reasons for the discrepancy among studies are presented. These include heterogeneity of patient selection, the nature of the studies, and the tumors themselves are responsible for varying results. Exogenous factors like alcohol consumption or metabolic syndrome confound these findings and suggest the need for statistical adjustments. The need for careful attention to the statistical details is exemplified, and the significant points of almost universal agreements are identified. The conclusion is that the definitive study is impossible for ethical and scientific reasons, and the physician should not ignore even simple personal observations and screening of all patients with extensive fibrosis in HCC, irrespective of sustained virologic response, until a robust, reliable prognostic model can be invented.

Keywords

Hepatocellular carcinoma / direct-acting antivirals / incidence / recurrence

References

[1] Salmon D,Maticic M.ESCMID Study Group for Viral HepatitisThe benefits of hepatitis C virus cure: every rose has thorns.J Viral Hepat2018;25:320-8

[2] Dang H,Yasuda S.Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both east and west.Hepatology2020;71:1910-22

[3] Park H,Henry L.Impact of all-oral direct-acting antivirals on clinical and economic outcomes in patients with chronic hepatitis c in the united states.Hepatology2019;69:1032-45 PMCID:PMC6393174

[4] Morgan RL,Smith BD,Pitasi M.Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies.Ann Intern Med2013;158:329-37

[5] Kanwal F,Asch SM,Cao Y.Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents.Gastroenterology2017;153:996-1005.e1

[6] Finkelmeier F,Peiffer KH.Risk of de novo hepatocellular carcinoma after hcv treatment with direct-acting antivirals.Liver Cancer2018;7:190-204 PMCID:PMC5985411

[7] Rutledge SM,Li DK.No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis.Hepatoma Res2019;5:31 PMCID:PMC6709867

[8] Semmler G,Kozbial K.Noninvasive risk stratification after HCV eradication in patients with advanced chronic liver Disease.Hepatology2021;73:1275-89 PMCID:PMC8252110

[9] Reig M,Perelló C.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.J Hepatol2016;65:719-26

[10] Rinaldi L,Coppola N.Hepatocellular carcinoma in hcv cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and posssible meanings.WCRJ2016; 3:748

[11] Kassas M, Tawheed A, Eltabbakh M, Kaseb A. Hepatitis C antiviral therapy in patients with successfully treated hepatocellular carcinoma: dancing with wolves.J Hepatocell Carcinoma2019;6:183-91 PMCID:PMC6879003

[12] Sapena V,Torres F.Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.Gut2022;71:593-604

[13] Hernaez R.End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.Gut2022;71:454-6

[14] Conti F,Scuteri A.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.J Hepatol2016;65:727-33

[15] Kozbial K,Schwarzer R.Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment.J Hepatol2016;65:856-8

[16] Ravi S,Jones D.Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis.Gastroenterology2017;152:911-2

[17] Cardoso H,Rodrigues S.High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.J Hepatol2016;65:1070-1

[18] Cabibbo G,Barbàra M.ITALI.CA study group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma.Liver Int2017;37:1157-66

[19] Calleja JL,Rincón D.Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating GroupEffectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort.J Hepatol2017;66:1138-48

[20] Lashen SA,Madkour MA.Hepatocellular carcinoma occurrence/recurrence after direct-acting antivirals for hepatitis C in egyptian cohort: single-center experience.Dig Dis2019;37:488-97

[21] Hassany SM,Abo-Alam H.Direct-acting antiviral drugs and occurrence of hepatocellular carcinoma: unjust or oppressed.Infect Drug Resist2020;13:1873-80 PMCID:PMC7308127

[22] Nakano M,Ide T.Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: a prospective multicenter cohort study.Cancer Med2019;8:2646-53 PMCID:PMC6536965

[23] Chan PPY,Shackel N,Prakoso E.Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.Hepatobiliary Pancreat Dis Int2020;19:541-6

[24] Ahn YH,Kim DY.Independent risk factors for hepatocellular carcinoma recurrence after direct-acting antiviral therapy in patients with chronic hepatitis C.Gut Liver2021;15:410-9 PMCID:PMC8129654

[25] Kamal A,Rostom YA,Lashen SA.Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study.Clin Exp Hepatol2021;7:66-73 PMCID:PMC8122091

[26] Degasperi E,Iavarone M.Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection.Clin Gastroenterol Hepatol2019;17:1183-1191.e7

[27] Mariño Z,Lens S.Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.J Hepatol2019;70:874-84

[28] Sangiovanni A,Gattai R.Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.J Hepatol2020;73:593-602

[29] Tani J,Moriya A.Long-term outcomes and evaluation of hepatocellular carcinoma recurrence after hepatitis C virus eradication by direct-acting antiviral treatment: all kagawa liver disease group (AKLDG) study.Cancers (Basel)2021;13:2257 PMCID:PMC8125844

[30] Ogawa E,Furusyo N.Kyushu University Liver Disease Study (KULDS) GroupLong-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals.J Gastroenterol Hepatol2022;37:190-9 PMCID:PMC9291903

[31] Yang JD,Pungpapong S,Roberts LR.Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.J Hepatol2016;65:859-60

[32] El Kassas M,Salaheldin M.Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: a comparative analysis.J Viral Hepat2018;25:623-30

[33] Fouad M,Ahmed E.Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients.World J Hepatol2021;13:1743-52. PMCID:PMC8637672

[34] Bielen R,Van Vlierberghe H.The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: a belgian experience.J Viral Hepat2017;24:976-81

[35] Fatima T,Khan MH.Patterns of hepatocellular carcinoma after direct antiviral agents and pegylated-interferon therapy.Cureus2020;12:e11565 PMCID:PMC7749863

[36] Nahon P,Bourcier V.ANRS CO12 CirVir GroupIncidence of hepatocellular carcinoma after direct antiviral therapy for HCV in Patients with cirrhosis included in surveillance programs.Gastroenterology2018;155:1436-1450.e6

[37] Kwong AJ,Flemming JA.De novo hepatocellular carcinoma among liver transplant registrants in the direct acting antiviral era.Hepatology2018;68:1288-97 PMCID:PMC6173633

[38] Lim N,Jackson S.Recurrence of hepatocellular carcinoma in hepatitis C virus (HCV) liver transplant recipients treated with pretransplant direct-acting antiviral (DAA) therapy.Gastrointest Tumors2020;7:134-43 PMCID:PMC7590751

[39] Kuo YH,Chang KC.The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.Invest New Drugs2020;38:202-10

[40] Teng W,Yang HI.Interferon is superior to direct acting antiviral therapy in tertiary prevention of early recurrence of hepatocellular carcinoma.Cancers (Basel)2019;12:23 PMCID:PMC7016942

[41] Karbeyaz F,Jaklin PJ.Rates of hepatocellular carcinoma after start of treatment for chronic hepatitis C remain high with direct acting antivirals: analysis from a swiss liver transplant center.J Hepatocell Carcinoma2021;8:565-74 PMCID:PMC8205644

[42] Ji D,Niu XX.Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.Metabol Open2021;10:100090 PMCID:PMC8050772

[43] Lithy RM,H Abdelmaksoud A.Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals.Eur J Gastroenterol Hepatol2022;34:227-34

[44] Rinaldi L,Guarino M.Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.J Transl Med2019;17:292 PMCID:PMC6712712

[45] Tayyab GUN,Nasir B,Abou-Samra AB.Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.BMC Gastroenterol2020;20:93 PMCID:PMC7137260

[46] Cheung MCM,Hudson BE.HCV Research UKOutcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.J Hepatol2016;65:741-7

[47] collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts); Electronic address: [e-mail]. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts.J Hepatol2016;65:734-40

[48] Mettke F,Deterding K.Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.Aliment Pharmacol Ther2018;47:516-25

[49] Carrat F,Dorival C.French ANRS CO22 Hepather cohortClinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.Lancet2019;393:1453-64

[50] Miuma S,Taura N.Influence of interferon-free direct-acting antiviral therapy on primary hepatocellular carcinoma recurrence: a landmark time analysis and time-dependent extended cox proportional hazards model analysis.Intern Med2020;59:901-7 PMCID:PMC7184089

[51] Kuromatsu R,Okamura S.Hepatitis C virus elimination using direct acting antivirals after the radical cure of hepatocellular carcinoma suppresses the recurrence of the cancer.Cancers (Basel)2022;14:2295 PMCID:PMC9103530

[52] Cabibbo G,Calvaruso V.Rete SICILIA SELEZIONE TERAPia - HCV (RESIST-HCV) and Italian Liver Cancer (ITALI.CA.) Group. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.J Hepatol2019;71:265-73

[53] Lin WC,Chang CW.Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.PLoS One2020;15:e0233212 PMCID:PMC7244104

[54] Singal AG,Mehta N.Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter north american cohort study.Gastroenterology2019;156:1683-1692.e1 PMCID:PMC6598433

[55] Nault JC.Can we move on from the discussion of direct antiviral agents and risk of hepatocellular carcinoma recurrence?.Gastroenterology2019;156:1558-60

[56] Serviddio G.The effect of direct-acting antivirals on hepatocellular carcinoma recurrence: still waiting for the turning point.Hepatobiliary Surg Nutr2019;8:525-6 PMCID:PMC6791973

[57] Mun EJ,Berry K.No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.Eur J Gastroenterol Hepatol2019;31:47-52 PMCID:PMC6279503

[58] Piñero F,Chagas A.Direct-acting antivirals and hepatocellular carcinoma: no evidence of higher wait-list progression or posttransplant recurrence.Liver Transpl2020;26:640-50

[59] Ikeda K,Kobayashi M.direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma.Dig Dis Sci2017;62:2932-42

[60] Lui FH,Patel A.Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis.Ann Gastroenterol2020;33:293-8 PMCID:PMC7196608

[61] Ochi H,Hirooka M.Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.J Gastroenterol2021;56:90-100 PMCID:PMC7819935

[62] Ikenaga H,Tamori A.Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment.J Viral Hepat2022;29:52-9

[63] Chen YS,Wang PM.The impact of direct-acting antiviral therapy on the risk of recurrence after curative resection in patients with hepatitis-C-virus-related early stage hepatocellular carcinoma.Medicina (Kaunas)2022;58:259 PMCID:PMC8875284

[64] Romano A,Piovesan S.Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study.J Hepatol2018;69:345-52

[65] Calvaruso V,Cacciola I.Rete Sicilia Selezione Terapia-HCV (RESIST-HCV)Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents.Gastroenterology2018;155:411-421.e4

[66] Huang P,Zang F.The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: a comprehensive analysis.Carcinogenesis2018;39:1497-505

[67] Jain A,Schreibman I.Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?.Hepatol Int2019;13:190-8

[68] Toyoda H,Uojima H.Characteristics and prognosis of de novo hepatocellular carcinoma after sustained virologic response.Hepatol Commun2021;5:1290-9 PMCID:PMC8279467

[69] Mecci AJ,Leen C.HCV Research UKThe association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.Aliment Pharmacol Ther2019;50:204-14

[70] Toyoda H,Tada T.The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: a prospective observational study.Liver Int2019;39:448-54

[71] Minami T,Nakagomi R.The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.J Hepatol2016;65:1272-3

[72] Nagata H,Asahina Y.Ochanomizu Liver Conference Study GroupEffect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.J Hepatol2017;67:933-9

[73] Waziry R,Grebely J.Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression.J Hepatol2017;67:1204-12

[74] Cammà C.Direct antiviral agents and risk of HCC: waiting for Godot.J Hepatol2018;68:614-6

[75] Li DK,Fierer DS.The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.Hepatology2018;67:2244-53

[76] Nishibatake Kinoshita M,Tateishi R.Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy.J Hepatol2019;70:78-86

[77] Gorgen A,Huang AC.The impact of direct-acting antivirals on overall mortality and tumoral recurrence in patients with hepatocellular carcinoma listed for liver transplantation: an international multicenter study.Transplantation2020;104:2087-96

[78] Janjua NZ,Darvishian M.The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk.J Viral Hepat2020;27:781-93

[79] Imai K,Hanai T,Shiraki M.Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment.Mol Clin Oncol2020;12:111-6 PMCID:PMC6951252

[80] Tahata Y,Urabe A.Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment.Hepatol Res2020;50:1118-27

[81] Wu KC,Chi CT.Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection.Am J Cancer Res2021;11:5526-42 PMCID:PMC8640813

[82] Chi CT,Su CW.Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan.J Microbiol Immunol Infect2021;54:385-95

[83] Ismail MS,Polychronopoulou E.Outcomes in the era of interferon-free direct-acting antiviral therapy after liver transplantation in patients with hepatitis C virus and hepatocellular carcinoma.J Hepatocell Carcinoma2021;8:701-11 PMCID:PMC8254565

[84] Ioannou GN,Berry K.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.J Hepatol2017:25-32 PMCID:PMC5837901

[85] Mashiba T,Kurosaki M.Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC?.PLoS One2018;13:e0194704 PMCID:PMC5901785

[86] Innes H,Hayes PC.The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen.J Hepatol2018;68:646-54

[87] Nagaoki Y,Nishida Y.The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: comparison with interferon-based therapy.J Med Virol2019;91:650-8

[88] Singer AW,Telep LE.Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.Aliment Pharmacol Ther2018;47:1278-87

[89] Frazzoni L,Metelli F.Hepatocellular carcinoma recurrence after hepatitis c virus therapy with direct-acting antivirals. a systematic review and meta-analysis.J Clin Med2021;10:1694 PMCID:PMC8071154

[90] Sapena V,Torres F.Reply to: “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules - a response”.J Hepatol2019;71:447-8

[91] Shiha G,Soliman R,Adel Elbasiony M.Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: a prospective study.J Viral Hepat2020;27:671-9

[92] Tani J,Sakamoto T.Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study.Oncol Lett2020;19:2205-12 PMCID:PMC7038998

[93] Hamoir C,Stärkel P,Negrin Dastis S.Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.Acta Gastroenterol Belg2021;84:25-32

[94] Altman DG.Absence of evidence is not evidence of absence.BMJ1995;311:485

[95] Koike K.Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways.J Gastroenterol Hepatol2007;22 Suppl 1:S108-11

[96] Zhao P,Xing S.Epigenetic mechanisms involved in HCV-induced hepatocellular carcinoma (HCC).Front Oncol2021;11:677926 PMCID:PMC8320331

[97] Hoshida Y,Kobayashi M.Gene expression in fixed tissues and outcome in hepatocellular carcinoma.N Engl J Med2008;359:1995-2004 PMCID:PMC2963075

[98] Hoshida Y,Sangiovanni A.Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis.Gastroenterology2013;144:1024-30 PMCID:PMC3633736

[99] Nakagawa S,Song WM.Precision Liver Cancer Prevention ConsortiumMolecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition.Cancer Cell2016;30:879-90 PMCID:PMC5161110

[100] Hayes CN,Zhang Y.Molecular mechanisms of hepatocarcinogenesis following sustained virological response in patients with chronic hepatitis C virus infection.Viruses2018;10:531 PMCID:PMC6212901

[101] Goto K,Wrensch F,Lupberger J.Hepatitis C virus and hepatocellular carcinoma: when the host loses its grip.Int J Mol Sci2020;21:3057 PMCID:PMC7246584

[102] Hengst J,Deterding K.Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy.Eur J Immunol2016;46:2204-10

[103] Reig M,Mariño Z,Forns X.Liver cancer emergence associated with antiviral treatment: An immune surveillance failure?.Semin Liver Dis2017;37:109-18

[104] Owusu Sekyere S,Mettke F.HCC Immune surveillance and antiviral therapy of hepatitis C virus infection.Liver Cancer2019;8:41-65 PMCID:PMC6388568

[105] Wedemeyer H,Strunz B.Reversal of immunity after clearance of chronic HCV infection-all reset?.Front Immunol2020;11:571166 PMCID:PMC7578424

[106] Perez S,Domovitz T.Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.PLoS Genet2019;15:e1008181 PMCID:PMC6602261

[107] Hamdane N,Crouchet E.HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response.Gastroenterology2019;156:2313-2329.e7 PMCID:PMC8756817

[108] Li MM,Gong YF.Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma.BMC Cancer2019;19:851 PMCID:PMC6714407

[109] Okamoto Y,Shimizu Y.Hepatitis virus infection affects DNA methylation in mice with humanized livers.Gastroenterology2014;146:562-72

[110] Zheng Y,Joyce BT.DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma.Clin Epigenetics2019;11:145 PMCID:PMC6802191

[111] Ponziani FR,Paroni Sterbini F.Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis.Aliment Pharmacol Ther2018;48:1301-11

[112] Tovo PA,Daprà V.Chronic HCV infection is associated with overexpression of human endogenous retroviruses that persists after drug-induced viral clearance.Int J Mol Sci2020;21:3980 PMCID:PMC7313012

[113] Santangelo L,Montaldo C.Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties.Liver Int2018;38:1741-50

[114] Butt AS,Abid S.Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: biologically plausible or an epiphenomenon?.World J Hepatol2018;10:267-76 PMCID:PMC5838445

[115] Takeda H,Iguchi E.Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus.Carcinogenesis2021;42:672-84

[116] Sung PS.Immunological mechanisms for hepatocellular carcinoma risk after direct-acting antiviral treatment of hepatitis C virus infection.J Clin Med2021;10:221 PMCID:PMC7827927

[117] Dash S,Widmer KE.Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of direct-acting antiviral treatment.J Hepatocell Carcinoma2020;7:45-76 PMCID:PMC7167284

[118] Aydin Y,Chandra PK.Interferon-alpha-induced hepatitis C virus clearance restores p53 tumor suppressor more than direct-acting antivirals.Hepatol Commun2017;1:256-69 PMCID:PMC5721446

[119] Aydin Y,Chava S.Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture.Sci Rep2017;7:9223 PMCID:PMC5569052

[120] Aydin Y,Song K.Hepatic stress response in HCV infection promotes STAT3-mediated inhibition of HNF4A-miR-122 feedback loop in liver fibrosis and cancer progression.Cancers (Basel)2019;11:1407 PMCID:PMC6827087

[121] Pinyol R,Wang H.Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.J Hepatol2021;75:865-78

[122] Villani R,Bellanti F.DAAs rapidly reduce inflammation but increase serum vegf level: a rationale for tumor risk during anti-HCV treatment.PLoS One2016;11:e0167934 PMCID:PMC5172554

[123] Faillaci F,Critelli R.Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals.Hepatology2018;68:1010-24

[124] Elmasry S,Bang BR.Detection of occult hepatitis c virus infection in patients who achieved a sustained virologic response to direct-acting antiviral agents for recurrent infection after liver transplantation.Gastroenterology2017;152:550-553.e8 PMCID:PMC5285320

[125] Yousif MM,Morad EA.Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents.Infez Med2018;26:237-43

[126] Abd Alla MDA,Rashed HAE.Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.Arch Virol2021;166:1071-81

[127] Matsuura K,Ikeo K.Japanese genome-wide association study group for viral hepatitisgenome-wide association study identifies TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus infection.Gastroenterology2017;152:1383-94

[128] Villani R,Serviddio G.Molecular mechanisms involved in HCC recurrence after direct-acting antiviral therapy.Int J Mol Sci2018;20:49 PMCID:PMC6337751

[129] Rinaldi L,Franci G.Risk of hepatocellular carcinoma after HCV clearance by direct-acting antivirals treatment predictive factors and role of epigenetics.Cancers (Basel)2020;12:1351 PMCID:PMC7352473

[130] Oe N,Eso Y,Marusawa H.Clinical and molecular basis of hepatocellular carcinoma after hepatitis C virus eradication.Pathogens2022;11:430 PMCID:PMC9028726

[131] Guarino M,Cossiga V,Caporaso N.Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the LiverDirect-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: a few lights and many shadows.World J Gastroenterol2018;24:2582-95 PMCID:PMC6021774

[132] Audureau E,Layese R.ANRS CO12 CirVir groupPersonalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.J Hepatol2020;73:1434-45

[133] D’Ambrosio R,Lampertico P.Predicting hepatocellular carcinoma risk in patients with chronic HCV infection and a sustained virological response to direct-acting antivirals.J Hepatocell Carcinoma2021;8:713-39 PMCID:PMC8254542

[134] Fujiwara N,Goossens N.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.J Hepatol2018;68:526-49 PMCID:PMC5818315

[135] Liu XN,Li YF,Liu G.Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis.World J Gastroenterol2019;25:4199-212 PMCID:PMC6700689

[136] Scheiner B,Kirstein MM.Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.J Hepatol2022;76:353-63

[137] Huo TI,Ho SY.Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?.J Hepatol2022;76:987-8

[138] Khakoo SI.Immunotherapy for hepatocellular carcinoma: a “CRAFITY” approach to patient stratification.Hepatobiliary Surg Nutr2022;11:327-9 PMCID:PMC9023814

[139] Thorsson V,Brown SD.Cancer genome atlas research networkThe immune landscape of cancer.Immunity2018;48:812-830.e14 PMCID:PMC5982584

[140] Bidkhori G,Klevstig M.Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes.Proc Natl Acad Sci U S A2018;115:E11874-83 PMCID:PMC6294939

[141] Rebouissou S.Advances in molecular classification and precision oncology in hepatocellular carcinoma.J Hepatol2020;72:215-29

[142] Jiang Y,Zhao Y.Chinese Human Proteome Project (CNHPP) ConsortiumProteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma.Nature2019;567:257-61

[143] Sun R,Zhang H.Mechanistic modeling of gene regulation and metabolism identifies potential targets for hepatocellular carcinoma.Front Genet2020;11:595242 PMCID:PMC7786279

[144] Krishnan MS,Park J.Genomic analysis of vascular invasion in HCC reveals molecular drivers and predictive biomarkers.Hepatology2021;73:2342-60 PMCID:PMC8115767

[145] Dhanasekaran R,Roberts LR.Genomic medicine and implications for hepatocellular carcinoma prevention and therapy.Gastroenterology2019;156:492-509 PMCID:PMC6340723

[146] Wu Y,Xu X.Molecular subtyping of hepatocellular carcinoma: a step toward precision medicine.Cancer Commun (Lond)2020;40:681-93 PMCID:PMC7743018

[147] Heinrich S,Ma L,Greten TF.Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.J Hepatol2021;74:700-15

[148] Dong X,Liu C.Single-cell analysis reveals the intra-tumor heterogeneity and identifies MLXIPL as a biomarker in the cellular trajectory of hepatocellular carcinoma.Cell Death Discov2021;7:14 PMCID:PMC7814056

[149] Alvarez M,Darci-Maher N.Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival.Genome Med2022;14:50 PMCID:PMC9115949

[150] Shimada S.Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma.Int J Clin Oncol2022;27:1101-9

[151] Galle PR.Decision making in systemic therapy of hepatocellular carcinoma: Should we pay attention to disease aetiology?.J Hepatol2021;75:763-4

[152] Kolly P,Vermehren J.Hepatocellular carcinoma recurrence after direct antiviral agent treatment: a European multicentre study.J Hepatol2017;67:876-8

[153] Adhoute X,Raoul JL.Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.Eur J Gastroenterol Hepatol2018;30:368-75

[154] Tsai PC,Yu ML.Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy.J Hepatol2017;66:464

[155] Singal AG,Kanwal F.AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review.Gastroenterology2019;156:2149-57 PMCID:PMC6529246

[156] Ogawa E,Nomura H.Kyushu University Liver Disease Study (KULDS) GroupShort-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.Aliment Pharmacol Ther2018;47:104-13

[157] Gao X,Wang L,Niu J.Timing of DAA initiation after curative treatment and its relationship with the recurrence of HCV-related HCC.J Hepatocell Carcinoma2020;7:347-60 PMCID:PMC7720283

[158] Wörns MA,Zeuzem S,Manns M.Drug treatment for chronic hepatitis C infection and cancer risk.Dtsch Arztebl Int2017;114:597-602 PMCID:PMC5615395

[159] Saraiya N,Rich NE,Parikh ND.Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.Aliment Pharmacol Ther2018;48:127-37 PMCID:PMC6019180

[160] Turgeon MK,Delman AM.Optimal timing of administration of direct-acting antivirals for patients with hepatitis c-associated hepatocellular carcinoma undergoing liver transplantation.Ann Surg2021;274:613-20 PMCID:PMC8559662

[161] Kogiso T,Kodama K.Hepatocellular carcinoma after direct-acting antiviral drug treatment in patients with hepatitis C virus.JGH Open2019;3:52-60 PMCID:PMC6386743

[162] Kuo MJ,Chen CL.Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.BMC Cancer2021;21:250

[163] Sanduzzi-Zamparelli M,Lens S.Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.J Hepatol2022;76:874-82

[164] Ramadori G,Moriconi F.Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy.BMC Cancer2018;18:257 PMCID:PMC5840818

[165] Samonakis DN,Coucoutsi C.Clinical outcomes of compensated and decompensated cirrhosis: a long term study.World J Hepatol2014;6:504-12 PMCID:PMC4110542

[166] Innes H,Hayes P.Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.J Hepatol2017;66:19-27

[167] Zayedi E,Teimoori A.Prevalence of hepatitis C virus among HIV-infected patients.Iran J Microbiol2020;12:156-63 PMCID:PMC7244820

[168] Minami T,Fujiwara N.Impact of obesity and heavy alcohol consumption on hepatocellular carcinoma development after HCV eradication with antivirals.Liver Cancer2021;10:309-19 PMCID:PMC8339497

[169] Semmler G,Kozbial K.HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.J Hepatol2022;76:812-21

[170] Kouroumalis E.Hepatitis C virus: a critical approach to who really needs treatment.World J Hepatol2022;14:1-44 PMCID:PMC8790391

[171] van der Meer AJ,Hofer H.Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.J Hepatol2017;66:485-93

[172] Degasperi E,Pelusi S.Hepatic fat-genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated With DAAs.Hepatology2020;72:1912-23

[173] D’Ambrosio R,Anolli MP.Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.J Hepatol2022;76:302-10

[174] Abdel-Razik A,El Nakib AM.De novo hepatocellular carcinoma in hepatitis C-related cirrhosis: are advanced glycation end products a key driver?.Front Cell Infect Microbiol2021;11:662431 PMCID:PMC8517490

[175] Váncsa S,Hegyi P.Diabetes mellitus increases the risk of hepatocellular carcinoma after direct-acting antiviral therapy: systematic review and meta-analysis.Front Med (Lausanne)2021;8:744512 PMCID:PMC8558240

[176] Luna-Cuadros MA,Hanif H,Khan MM.Risk of hepatocellular carcinoma after hepatitis C virus cure.World J Gastroenterol2022;28:96-107 PMCID:PMC8793019

[177] Salmon-Ceron D,Layese R.ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groupsHuman immunodeficiency virus/hepatitis C virus (HCV) Co-infected patients with cirrhosis are no longer at higher risk for hepatocellular carcinoma or end-stage liver disease as compared to HCV mono-infected patients.Hepatology2019;70:939-54

[178] Corma-Gómez A,Lacalle-Remigio JR.RIS-HEP13 and GEHEP 011 study groupsHuman immunodeficiency virus (HIV) infection is associated with lower risk of hepatocellular carcinoma after sustained virological response to direct-acting antivirals in hepatitis c infected patients with advanced fibrosis.Clin Infect Dis2021;73:e2109-16

[179] Quaranta MG,Monti M.PITER Collaborating GroupAdvanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort.Hepatol Int2020;14:362-72 PMCID:PMC7220859

[180] Ioannou GN,Green PK.Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores.Gastroenterology2019;157:1264-1278.e4

[181] Flisiak R,Janczewska E.Five-year follow-up of cured HCV patients under real-world interferon-free therapy.Cancers (Basel)2021;13:3694 PMCID:PMC8345092

[182] Pons M,Esteban JI.Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.J Hepatol2020;72:472-80

[183] Piñero F,Ridruejo E.LALREANTreatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.Liver Int2019;39:1033-43

[184] Singh S,Loke YK.Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis.Frontline Gastroenterol2018;9:262-70 PMCID:PMC6145438

[185] Burlone ME,Croce A.Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment.Hepatoma Res2020;6:3

[186] Pazgan-simon M.Direct acting antivirals therapy and hepatocellular carcinoma risk in patients with hepatitis C virus.Hepatoma Res2020;6:17

[187] Yang M,Huang Y.Impact of direct-acting antivirals on.Hepatoma Res2020;6:31

[188] Yoo SH.The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C.Hepatoma Res2020;6:9

[189] D'Ambrosio R.Hepatocellular carcinoma risk, outcomes, and screening after hepatitis C eradication.Hepatol Commun2021;5:1465-8 PMCID:PMC8435272

[190] Sánchez-Azofra M,García-Buey ML.Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals.Liver Int2021;41:2885-91

[191] Alonso López S,Gea F.A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis.Hepatology2020;72:1924-34

[192] Ioannou GN,Beste LA.Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis.JAMA Netw Open2020;3:e2015626 PMCID:PMC7489819

[193] Muzica CM,Huiban L.Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: a debate near the end.World J Gastroenterol2020;26:6770-81 PMCID:PMC7684455

[194] Rinaldi B,Galiero R,Fasano M.Editorial - direct-acting antivirals therapy in HCV patients with HCC: lights and shadow.Eur Rev Med Pharmacol Sci2021;25:7622-5

[195] John BV.No association between direct-acting antivirals and hepatocellular carcinoma progression on the waiting list: time to put this controversy to rest?.Liver Transpl2020;26:621-3

[196] Celsa C,Giuffrida P.Direct-acting antiviral agents and risk of Hepatocellular carcinoma: critical appraisal of the evidence.Ann Hepatol2022;27 Suppl 1:100568

[197] Dajti E,Festi D.Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk.Hepatobiliary Surg Nutr2020;9:505-7

[198] Compagnoni S,Madonia G,Madonia S.Direct antiviral agents in hepatitis C virus related liver disease: don’t count the chickens before they're hatched.World J Gastroenterol2021;27:2771-83 PMCID:PMC8173378

[199] Sanduzzi-Zamparelli M,Leal C.Hepatocellular carcinoma recurrence in HCV patients treated with direct antiviral agents.Viruses2019;11:406 PMCID:PMC6563506

[200] Kassas M, Elbaz T, Salaheldin M, Abdelsalam L, Kaseb A, Esmat G. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: the debate continues - a mini-review.J Adv Res2019;17:43-8 PMCID:PMC6526204

[201] Kamal A,Abdelnabi M.Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate.World J Clin Cases2022;10:1764-74 PMCID:PMC8891795

[202] Lee CH.Direct-acting antiviral therapy and risk of hepatocellular carcinoma recurrence in patients with chronic hepatitis C.Gut Liver2021;15:327-8 PMCID:PMC8129652

[203] Meier V,Mihm S,Ramadori G.Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection.J Med Virol2003;69:50-8

[204] You MW,Shim JJ.Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: a systematic review and time-to-event meta-analysis.J Gastroenterol Hepatol2021;36:601-8

[205] Janjua NZ,Kuo M.Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.J Hepatol2017;66:504-13

[206] Rimassa L,Czauderna C,Galle P.Systemic treatment of HCC in special populations.J Hepatol2021;74:931-43

[207] Poynard T,Ratziu V.Truth survival in clinical research: an evidence-based requiem?.Ann Intern Med2002;136:888-95

[208] Koretz RL.Truth is not determined by a majority vote.Gastroenterology2003;124:1153-5